The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Renal cell carcinoma is a heterogenous cancer composed of an increasing number of
unique subtypes each with their own cellular and tumor behavior. The study of hereditary …

Background Few treatment options are available for patients with advanced renal cell
carcinoma who have received previous anti-PD-1-based or anti-PD-L1-based …

Background Although, micropeptides encoded by non-coding RNA have been shown to
have an important role in a variety of tumors processes, there have been no reports on …

Background Results from the phase 3 CLEAR study showed that lenvatinib plus
pembrolizumab improved progression-free survival and overall survival compared with …

Previous analyses of KEYNOTE-426, an open-label, phase 3 randomized study, showed
superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell …

Background Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with
new combination therapies demonstrating improved response rates and survival. There are …

Simple Summary Positron emission tomography/computed tomography (PET/CT) with
prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals is a relatively …

Background Improved markers for predicting recurrence are needed to stratify patients with
localised (stage I–III) renal cell carcinoma after surgery for selection of adjuvant therapy. We …

Objective Renal cell carcinomas represent the sixth-and tenth-most frequently diagnosed
cancer in men and women. Recently, percutaneous-guided thermal ablations have proved …